IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178526 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Katarina Vuleta Nedic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia. Hauptthemen laut MEDLINE: Interleukin-33, Neuroendocrine Tumors, Biomarkers, Tumor. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Kragujevac, Faculty of Medical Sciences, (Junior Project N° 12/24)., University of Kragujevac, Faculty of Medical Sciences.
Abstract (Originalsprache)
Despite a high disease control rate in the treatment of unresectable or metastatic well-differentiated, somatostatin receptor-positive neuroendocrine tumors (NETs) with peptide receptor radionuclide therapy (PRRT), a certain percentage of patients will experience an unfavorable outcome. Besides clinical, hematological, and biochemical parameters, including widely used inflammatory markers, as well as literature-recognized inflammatory indices, there is a growing need for the identification of novel biomarkers as prognostic factors of therapeutic response. In this prospective single-center study, 51 NET patients treated with PRRT were included and divided into two groups: responders and non-responders in accordance with therapeutic outcome. Cytokine, clinical, and biochemical data were analyzed. Non-responders had significantly higher serum concentrations of IL-33 and IL-4 in comparison to responders, while sST2 was increased in responders. A positive correlation was measured between IL-33 and IL-4, as well as between IL-33 and disease progression. A negative correlation was noted between IL-33 and the neutrophil count %. ROC curve analysis identified values of IL-33 >146.5 pg/mL as a predictor of poor early therapeutic response, and logistic regression confirmed its independent prognostic value. Elevated IL-33 and IL-4 favor the development of a type 2 immune response associated with unfavored therapeutic outcome, while increased sST2 mitigates the IL-33’s effect in responders, contributing to a more favorable response. These findings emphasize IL-33 as an important biomarker of early response in NET patients undergoing PRRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Clinical Oncology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Department for Nuclear Medicine, University Clinical Center Kragujevac, 34000 Kragujevac, Serbia.
- Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Faculty of Medicine, University of East Sarajevo, 73300 Foca, Bosnia and Herzegovina.
- Department of Clinical Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
- Department of Otorhinolaryngology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
ORCID-Profile: Katarina Vuleta Nedic, Nevena Gajovic, Ivan Jovanovic, Marina Jovanovic, Jelena Djordjevic, Vesna Ignjatovic, Vladimir Vukomanovic
Förderung
- University of Kragujevac, Faculty of Medical Sciences, (Junior Project N° 12/24).
- University of Kragujevac, Faculty of Medical Sciences
Zitieren
APA
Vuleta Nedic, K., Gajovic, N., Jovanovic, I., Jurisevic, M., Jovanovic, M., Jakovljević, S., Popovic, B., Djordjevic, J., Ignjatovic, V., & Vukomanovic, V. (2025). IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178526
Vancouver
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, et al. IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178526
BibTeX
@article{VuletaNedic2025,
author = {Vuleta Nedic, Katarina and Gajovic, Nevena and Jovanovic, Ivan and Jurisevic, Milena and Jovanovic, Marina and Jakovljević, Slobodan and Popovic, Bojana and Djordjevic, Jelena and Ignjatovic, Vesna and Vukomanovic, Vladimir},
title = {IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178526}
}
EUVIMED